3692.HK Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 11:08):

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People's Republic of China...

Stats
Šios dienos apimtis	6.48M
Vidutinė apimtis	5.62M
Rinkos kapitalizacija	103.65B
EPS	HKD0 ( 2024-03-26 )
Last Dividend	HKD0.0707 ( 2023-09-15 )
Next Dividend	HKD0 ( N/A )
P/E	31.21
ATR14	HKD0.0180 (0.10%)

Tūris Koreliacija

Ilgas: 0.04 (neutral)

Trumpas: -0.52 (weak negative)

Signal:(69.894) Neutral

Hansoh Pharmaceutical Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Hansoh Pharmaceutical Koreliacija - Valiuta/Žaliavos

-0.34
( neutral )

-0.38
( neutral )

0.00
( neutral )

-0.58
( weak negative )

-0.15
( neutral )

0.70
( moderate )

Hansoh Pharmaceutical Finansinės ataskaitos

Annual	2023
Pajamos:	HKD10.10B
Bruto pelnas:	HKD9.07B (89.78 %)
EPS:	HKD0.520

FY	2023
Pajamos:	HKD10.10B
Bruto pelnas:	HKD9.07B (89.78 %)
EPS:	HKD0.520

FY	2022
Pajamos:	HKD9.38B
Bruto pelnas:	HKD8.51B (90.73 %)
EPS:	HKD0.440

FY	2021
Pajamos:	HKD9.94B
Bruto pelnas:	HKD9.07B (91.24 %)
EPS:	HKD0.460

Financial Reports:

No articles found.

Hansoh Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0.0500 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0.0500 (N/A)	HKD0.141 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

Hansoh Pharmaceutical Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 6.64 - Stable (32.86%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	HKD0.0771	2021-06-07
Last Dividend	HKD0.0707	2023-09-15
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	8	--
Total Paid Out	HKD0.576	--
Avg. Dividend % Per Year	0.00%	--
Score	3.76	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	6.64
Div. Directional Score	8.95	--

Next Divdend (Est)
(2024-09-27)

HKD0.0743 Estimate 11.67 %

Dividend Stability

0.47 Below Average

Dividend Score

3.76

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
3838.HK	Ex Dividend Junior	2023-06-12	Annually	0.00%
1723.HK	Ex Dividend Junior	2023-09-04	Sporadic	0.00%
0759.HK	Ex Dividend Junior	2023-10-09	Sporadic	0.00%
2318.HK	Ex Dividend Knight	2023-09-11	Semi-Annually	0.00%
1286.HK	Ex Dividend Knight	2023-08-21	Semi-Annually	0.00%
0347.HK	No Dividend Player	2023-06-01	Sporadic	0.00%
6099.HK	Ex Dividend Junior	2023-07-14	Annually	0.00%
1848.HK	Ex Dividend Junior	2023-09-07	Semi-Annually	0.00%
0874.HK	Ex Dividend Knight	2023-06-14	Annually	0.00%
0023.HK	Ex Dividend Knight	2023-09-07	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.324	1.500	3.51	5.27	[0 - 0.5]
returnOnAssetsTTM	0.0992	1.200	6.69	8.03	[0 - 0.3]
returnOnEquityTTM	0.131	1.500	9.65	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	4.21	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	4.02	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	3.27	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.130	-1.500	7.84	-10.00	[0 - 0.6]
interestCoverageTTM	0	1.000	-1.111	-1.111	[3 - 30]
operatingCashFlowPerShareTTM	0.174	2.00	9.94	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.160	2.00	9.92	10.00	[0 - 20]
debtEquityRatioTTM	0.166	-1.500	9.34	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.898	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	0.265	1.000	6.70	6.70	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.267	1.000	9.63	9.63	[0.2 - 2]
assetTurnoverTTM	0.306	0.800	-1.295	-1.036	[0.5 - 2]
Total Score				11.25

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	33.03	1.000	6.76	0	[1 - 100]
returnOnEquityTTM	0.131	2.50	9.78	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.160	2.00	9.95	10.00	[0 - 30]
dividendYielPercentageTTM	1.166	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.174	2.00	9.94	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	4.64	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.113	1.000	9.66	0	[0.1 - 0.5]
Total Score				6.64

Hansoh Pharmaceutical

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including central nervous system diseases, oncology, anti-infectives, and metabolic diseases. Its principal products include Mailingda, a drug for the treatment of chronic myelogenous leukemia; and Ameile, Hansoh Xinfu, Pulaile, Zefei, Xinwei, Xinmei, Xintai, Tanneng, Oulanning, Ameining, Zetan, Hengjie, Hengsen, Fulaimei, Fulaidi, and Ruibote drugs. The company serves pharmaceutical product distributors. It has a strategic collaboration with Scynexis, Inc. to develop and commercialize ibrexafungerp for treatment of vaginal yeast infections; and strategic collaboration with Keros to develop, manufacture, and commercialize KER-050 for treatment of cytopenias, anemia, and thrombocytopenia. The company also has a collaboration with Olix Pharmaceuticals for development of drug candidates for cardiovascular, metabolic, and other diseases associated with the liver; and strategic collaboration with Silence Therapeutics plc to develop siRNAs for three targets leveraging Silence's mRNAi GOLD platform. The company was founded in 1995 and is headquartered in Lianyungang, the People's Republic of China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.